Assessment of quality of life in patients receiving monoclonal antibody therapy for cancer.
Document Type
Article
Department
Haematology and Oncology, East Africa
Abstract
Monoclonal antibody (mAb) therapy has emerged as a critical treatment modality for various cancers, offering targeted therapeutic options with improved clinical outcomes. However, the impact of these therapies on patients' quality of life (QoL) remains an essential factor in evaluating their overall effectiveness. This study aims to assess the QoL in patients receiving mAb therapy for cancer, using both quantitative and qualitative measures. A cohort of cancer patients undergoing mAb treatment was surveyed, with QoL evaluated through standardized instruments such as the EORTC QLQ-C30 and FACT-G, alongside patient interviews. Key domains analyzed included physical functioning, emotional well-being, fatigue, and pain management.
Publication (Name of Journal)
Journal of Immunotherapy
Recommended Citation
L, T.,
K, E.,
P, W.,
Saleh, M.
(1993). Assessment of quality of life in patients receiving monoclonal antibody therapy for cancer.. Journal of Immunotherapy, 14(4), 359.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/129
Comments
This work was published before the author joined Aga Khan University.